Clinical Trials Logo

Lead Poisoning clinical trials

View clinical trials related to Lead Poisoning.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05950386 Recruiting - Neurotoxicity Clinical Trials

Effects of Lead Exposure on Ferroptosis Pathway

Start date: July 1, 2023
Phase:
Study type: Observational

The aim of this study was to investigate the effects of chronic lead exposure on iron metabolism and the Nrf2-dependent ferroptosis pathway in lead acid battery factory workers

NCT ID: NCT03256383 Recruiting - Lead Poisoning Clinical Trials

Plan for Testing Fingerstick Bloods on Magellan Systems

Start date: July 31, 2017
Phase: N/A
Study type: Observational

This study is to supplement our internal data that demonstrates the continued performance of capillary blood samples on Magellan's lead testing systems: LeadCare II, LeadCare Ultra (which have been cleared previously by FDA), and PediaStat, which is an upgraded LeadCare II instrument in development.

NCT ID: NCT00926406 Recruiting - Inflammation Clinical Trials

Environmental Exposure to Lead and Its Health Effects on Patients With Maintenance Hemodialysis

Start date: April 2010
Phase: N/A
Study type: Interventional

One thousand patients with LHD who have no history of exposure to lead will be observed for 18 months. Blood lead level(BLL), biochemical data, hemoglobin, albumin, Cr, high sensitivity C-reactive protein (HsCRP), and blood cell counts are assessed at baseline. The morbidity and mortality are recorded in detail. Then, one hundred subjects with high BLL (>20μg/dl) will be randomly assigned to the study and control groups. For 3-6 months, the 50 patients in the study group will receive lead-chelation therapy with calcium disodium EDTA weekly until the BLB falls below BLL< 5 μg/dl, and the 50 control group patients receive weekly placebo for 12 weeks. During the ensuing 18 months, the BLL, biochemical data will be regularly followed up every 3 months. BLL is measured every 6 months. If BLL of the study group patients increase >10 μg/dl, the chelation therapy will be performed again until their BLL is <5 μg/dl. The primary end point is morbidity or mortality during the observation and follow-up period. A secondary end point is the change in hemoglobin, albumin, Cr and Hs CRP during the follow up period.